OncoMatch/Clinical Trials/NCT07125391
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Is NCT07125391 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Propranolol Hydrochloride and Paclitaxel liposome for ovarian cancer.
Treatment: Propranolol Hydrochloride · Paclitaxel liposome · Carboplatin — Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors. Cytoreductive Surgery (CRS) combined with chemotherapy is the standard treatment for patients with advanced ovarian cancer. However, most of the ovarian cancer is stage Ⅲ and above, and there may be a certain degree of organ metastasis. Preclinical studies have found that the stress of melanoma block beta adrenergic signals in mice, which USES beta blockers, checkpoint will enhance resistance to PD - 1 the activity of the inhibitor, to improve the treatment of mice on the immune response. Non-selective β-blockers can also improve the efficacy of melanoma immunotherapy. Retrospective studies have shown that incidental use of β-blockers in combination with antiangiogenic agents, chemotherapy, and immune therapy can prolong DFS, PFS, and OS in cancer patients. A large, multicenter retrospective study found that ovarian cancer patients who took nonselective β-blockers for hypertension had better survival than those who did not. In conclusion, this study aims to explore new auxiliary chemotherapy combined propranolol treatment of high efficacy and safety of ovarian cancer, provide more evidence-based basis for clinic.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV
Grade: high-grade
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: pelvic radiotherapy
Cannot have received: systemic chemotherapy for ovarian cancer
Cannot have received: tumor targeting therapy
Cannot have received: immune therapy
Lab requirements
Blood counts
hemoglobin (hgb) 90 g/l or higher; neutrophils (neut) 1.5 x 10^9 / l or wbc 3 x 10^9 / l; platelet (plt) 90 x 10^9 / l or higher
Kidney function
serum creatinine 1.0 x uln or less
Liver function
ast 2.5 x uln or less; alt 2.5 x uln or less; total bilirubin 1.5 x uln or less
Cardiac function
no severe heart dysfunction; exclusion of significant ecg abnormalities, unstable angina, congestive heart failure (nyha ≥2), recent arterial thrombosis/embolism/ischemia (within 6 months), or severe arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07125391 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy, systemic chemotherapy for ovarian cancer, tumor targeting therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages